- GMP
About
Recipharm is a global CDMO that develops and manufactures pharmaceutical products for small and large molecules, including oral solid doses, semi-solids, liquids, sterile products, controlled substances, vaccines, and advanced biologics. It serves pharmaceutical, biotech, veterinary, and other customers from a global network of facilities with local expertise.
Services
Oral solid dose development
Develops oral solid dose products from early phases to manufacturing readiness using a Quality-by-Design approach.
Oral solid dose manufacturing
Manufactures powders, granules, tablets, pellets, and hard capsules, including coated, uncoated, immediate-release, modified-release, and controlled-release forms.
Semi-solid formulation development and manufacturing
Develops and manufactures topical and transdermal semi-solid products such as creams, gels, ointments, pastes, and suppositories.
Liquid formulation and manufacturing
Develops and manufactures non-sterile and sterile liquid dosage forms including solutions, emulsions, suspensions, sprays, and aerosols.
Sterile vial filling
Provides aseptic vial filling and terminal sterilisation for liquid-filled or lyophilised vial products.
Pre-filled syringe and cartridge filling
Offers sterile filling of pre-filled syringes and pharmaceutical cartridges for parenteral products, including complex formulations.
Sterile lyophilisation
Provides aseptic freeze-drying and lyophilisation cycle development and optimisation for sterile pharmaceutical products.
Vaccine manufacturing
Supports vaccine manufacturing and aseptic fill-finish, including liquid and lyophilised mRNA COVID-19 vaccines.
Parenteral drug development
Supports formulation development and sterility testing for injectable drugs, including solutions, suspensions, and lyophilised products.
Technology transfer
Supports transfer of data, materials, knowledge, manufacturing, and quality control methods between sites or to third parties.
New product introduction (NPI)
Manages the design and manufacturing introduction of new therapeutics and supports clinical and commercial product transfer.
Product development
Provides formulation and process development using DoE and QbD for new chemical entities and generics.
ReciPredict
Uses statistical modelling and simulation to support product development, tech transfer, and manufacturing decisions.
Controlled substance manufacturing
Supports import, storage, manufacture, export, and analytical services for Schedule I-V controlled substances.
Animal health drug product manufacturing
Manufactures veterinary dosage forms including liquids, semi-solids, sterile injectables, antibiotics, and anaesthetics.
Solid dosage form development and manufacturing
Development and manufacturing solutions for solids, semi-solids, and liquid dosage forms.
Sterile fill & finish
Sterile fill and finish development and manufacturing for biologics and small molecules.
Lyophilisation
Aseptic lyophilisation and sterile freeze-drying services, including cycle development and scale-up.
Blow-fill-seal filling
Aseptic unidose production using blow-fill-seal technology, from concept to commercial manufacturing.
Ampoule manufacturing
Manufacturing services for ampoules as part of sterile delivery offerings.
OSD drug development
Oral solid dose development services, including formulation and process development.
Analytical development
Analytical method development and supporting development services.
Pharmaceutical analytical services
Method development, validation, impurity identification, stability studies, and release testing.
Regulatory excellence
Regulatory support services offered as part of additional services.
New product introduction
Support for introducing new products and transferring processes into manufacturing.
Microbial & live biotherapeutic products
Development and GMP manufacture of microbial and live biotherapeutic products.
Recombinant proteins
Development and GMP manufacture of recombinant proteins.
Virus & viral vectors
Development and GMP manufacture of viral vectors and virus-based products.
xRNA therapies
Development and GMP manufacture of xRNA therapies.
Capabilities
- Assays and studies
- Lyophilization · Fill-finish · Analytical development · mRNA · Process development · Small molecules · Sterility testing · Endotoxin testing · Pharmacopoeia testing · Method development · Method validation · Stability testing
14 more
Dissolution studies · Release analytics · Elemental impurities · Nitrosamine analytics · Container closure integrity testing · Viable particulate analysis · Non-viable particulate analysis · Extractables and leachables · Impurity identification · Stability studies · Release testing · Pharmacopeial testing · Extractables and leachables (E&L) · Elemental impurities testing - Scale and capacity
- 16 facilities in 8 countries · Commercial-scale manufacturing · Clinical trial manufacturing · High-volume vaccines · Billions of doses of sterile products · Up to OEB 5 · 17 facilities · 8 countries · 4,500+ people · More than 250 ongoing stability studies concurrently
- Therapeutic areas
- Vaccines · Animal health · Biologics · Injectables · Ophthalmics · Pulmonary
Instruments and platforms
- Relevant to not stated
- Mass spectrometry
- High-resolution mass spectrometry
- Preparative HPLC
- NMR
Modalities and species
- Modalities
- Small molecule · mRNA · Viral vector · Cell therapy · Recombinant protein · Vaccine · Plasmid DNA
- Species and models
- NCEs · Generics · Pharmaceuticals · Biotech products · Veterinary products · Schedule I-V controlled substances
Certifications
As the company states them, with the certificate or registry record where there is one.
GMPSelf-reported
As listed: cGMP
ISO 14001Self-reported
Company
- Type
- CDMO
- Founded
- 1995
- Team
- 4,500+ people
Locations
- Based in
- Kayserberg, France
- Serves
- global, Europe, USA
Public records
- Wikidata
- Q7302454 source
Similar labs
Work here? Claim this listing